PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT02335905: Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
Official title: Phase 1/2 Trial of Ceftaroline for the Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
Conditions: Hematogenously Acquired Staphylococcus Aureus Osteomyelitis
Bone Infection
Osteomyelitis
Summary: This research study is looking at an antibiotic medicine, Ceftaroline Fosamil (Ceftaroline), which fights infections like the one the subject has. Ceftaroline is effective against S.aureus germs including those that are called Methicillin Resistant Staphylococcus aureus (MRSA.)
Ceftaroline has been approved by the U.S. Food and Drug Administration (FDA) for use in adults and children with Community-Acquired Bacterial Pneumonia [a type of lung infection] and Acute Bacterial Skin and Skin Structure Infections. Ceftaroline is not yet approved for treatment in subjects with hematogenous osteomyelitis, therefore, the use of Ceftaroline in this research study is considered "investigational".
The goal of this research study is to find out what side effects there may be when children are taking Ceftaroline and to study how effective Ceftaroline is in treating bone infections due to Staphylococcus aureus in children. The investigators are also studying what the body does to the study drug, Ceftaroline, and if the doses the investigators use result in blood levels that the investigators think are going to be effective against bone infections in children. This is called pharmacokinetics (PK).
Interventions:
description: IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
name: Ceftaroline Fosamil
type: Drug
Study arms:
design_group_description: IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.
design_group_title: Ceftaroline Fosamil
design_group_type: Experimental
Sponsor: Baylor College of Medicine
Collaborators: Allergan UC
Drug name mappings:
name: 醋酸头孢洛林酯
lang: CN
name: Ceftaroline Fosamil
lang: EN
Clinical trial NCT02178722: Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Official title: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)
Conditions: Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
Endometrial Cancer
Head and Neck Cancer
Hepatocellular Carcinoma (HCC)
Gastric Cancer
Lung Cancer
Lymphoma
Renal Cell Carcinoma (RCC)
Ovarian Cancer
Solid Tumors
UC (Urothelial Cancer)
Melanoma
Bladder Cancer
Triple Negative Breast Cancer (TNBC)
Summary: The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
Interventions:
description: IV infusion
name: MK-3475
type: Drug
description: Oral daily dosing
name: INCB024360
type: Drug
Study arms:
design_group_description: Phase 1: MK-3475 + INCB024360 25 mg twice a day (BID) as starting dose, followed by dose escalations (Phase 1) until recommended phase 2 dose of INCB024360 is determined
design_group_title: Phase 1: MK-3475 + INCB024360
design_group_type: Experimental
design_group_description: (recommended phase 2 dose)
design_group_title: Phase 2: MK-3475 + INCB024360
design_group_type: Experimental
Sponsor: Incyte Corp.
Collaborators: Merck Sharp & Dohme Corp.
Drug name mappings:
name: 帕博利珠单抗
lang: CN
name: Pembrolizumab
lang: EN
name: ペムブロリズマブ（遺伝子組換え）
lang: JP
name: 艾卡哚司他
lang: CN
name: Epacadostat
lang: EN
Clinical trial NCT03493282: Effect of CT1812 Treatment on Brain Synaptic Density
Official title: A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease
Conditions: Alzheimer Disease
Summary: Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
Interventions:
description: CT1812
name: Active Treatment- CT1812 100 mg
type: Drug
description: CT1812
name: Active Treatment- CT1812 300 mg
type: Drug
description: Matching Placebo
name: Placebo
type: Drug
Study arms:
design_group_description: High Dose CT1812
design_group_title: 300 mg
design_group_type: Active Comparator
design_group_description: Low Dose CT1812
design_group_title: 100 mg
design_group_type: Active Comparator
design_group_description: Matching Placebo
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Cognition Therapeutics, Inc.
Collaborators: National Institute on Aging
Drug name mappings:
name: Zervimesine
lang: EN
Clinical trial NCT00886795: Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
Official title: A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy.
Conditions: Urticaria
Summary: This study is being done to find out if a drug called Abatacept (Orencia ®) is safe and effective in treating people with chronic urticaria (persistent hives).
Interventions:
description: 4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
name: abatacept (Orencia ®)
other_name: orencia
type: Drug
Study arms:
design_group_description: 4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 weeks, and 8 weeks.
design_group_title: Abatacept
design_group_type: Experimental
Sponsor: The Johns Hopkins University
Collaborators: Bristol Myers Squibb Co.
Drug name mappings:
name: 阿巴西普
lang: CN
name: Abatacept
lang: EN
name: アバタセプト（遺伝子組換え）
lang: JP
Clinical trial NCT03732274: Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
Official title: Phase 1b/2a, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Durvalumab in Patients With Advanced Non Small Cell Lung Cancer Who Progressed Following Platinum-based Chemotherapy
Conditions: Non-Small Cell Lung Cancer Metastatic
Summary: This is an open -label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination with durvalumab in patients advanced NSCLC who progressed following platinum-based chemotherapy.
Interventions:
description: TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.
name: TEW-7197
other_name: vactosetib
type: Drug
Study arms:
design_group_description: TEW-7197 will be administered orally for 5 days per week (5D/W) and Durvalumab administration.
design_group_title: Dose Escalation of TEW-7197
design_group_type: Experimental
Sponsor: MedPacto, Inc.
Collaborators: AstraZeneca PLC
Drug name mappings:
name: Vactosertib
lang: EN
Clinical trial NCT05518188: Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
Official title: A Phase 1/2 Open-label Intrathecal Administration of MELPIDA to Determine Its Safety and Efficacy for Patients with Spastic Paraplegia Type 50 (SPG50) Caused by Mutation in the AP4M1 Gene.
Conditions: Spasticity, Muscle
Microcephaly
Intellectual Deficiency
Growth Retardation
SPG50
Spastic Paraplegia
Summary: MELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal injection to counter the associated neuronal loss. Outcomes will evaluate the safety and tolerability of a single dose of MELPIDA, which will be measured by the treatment-associated adverse events (AEs) and serious adverse events (SAEs). Secondarily, the trial will explore efficacy in terms of disease burden assessments.
Interventions:
description: MELPIDA, a recombinant serotype 9 adeno-associated virus (AAV) encoding a codon-optimized human AP4M1 transgene
name: MELPIDA
type: Biological
Study arms:
design_group_description: MELPIDA, a gene therapy product
design_group_title: Treatment Arm
design_group_type: Experimental
Sponsor: Elpida Therapeutics
Collaborators: The University of Texas Southwestern Medical Center
Drug name mappings:
name: Melpida
lang: EN
Clinical trial NCT00794417: A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Official title: A Phase 1/2 Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma
Conditions: Advanced Carcinoma
Non-small Cell Lung Cancer
Summary: The purpose of the study was to determine whether the combination of aflibercept, pemetrexed and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).
Interventions:
description: Administered in combination with the other two interventions via intravenous infusion.
name: Aflibercept
type: Drug
description: Administered in combination with the other two interventions via intravenous infusion.
name: Pemetrexed
other_name: Alimta
type: Drug
description: Administered in combination with the other two interventions via intravenous infusion.
name: Cisplatin
other_name: Platinol
type: Drug
Study arms:
design_group_description: Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
design_group_title: Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
design_group_type: Experimental
design_group_description: Participants received intravenous infusion of aflibercept 2 milligrams per kilogram (mg/kg) followed by pemetrexed 500 mg/square meter (m^2) and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
design_group_title: Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin
design_group_type: Experimental
design_group_description: Participants received intravenous infusion of aflibercept 4 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
design_group_title: Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin
design_group_type: Experimental
design_group_description: Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) for 6 cycles.
design_group_title: Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
design_group_type: Experimental
Sponsor: Regeneron Pharmaceuticals, Inc.
Collaborators: Sanofi
Drug name mappings:
name: 阿柏西普
lang: CN
name: Aflibercept
lang: EN
name: アフリベルセプト（遺伝子組換え）
lang: JP
name: 培美曲塞二钾
lang: CN
name: Pemetrexed Dipotassium
lang: EN
name: 顺铂
lang: CN
name: Cisplatin
lang: EN
name: シスプラチン
lang: JP
Clinical trial NCT02573857: A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Official title: A Phase Ib Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Conditions: Malaria
Summary: Part A
-Cohort 1 DSM265 will be administered as a single dose (400 mg). For cohort 1 only, an additional single dose (400 mg) of DSM265 may be given if gametocytemia develops. Treatment with DSM265 will be given after an overnight fasting period of ≥ 8 hours. If dosing is to occur in the evening, subjects will be required to fast for ≥4 hours prior to receiving treatment. Subjects will be required to fast for a further four hours anytime after dosing with DSM265.
Part B
* Cohort 2 OZ439 will be administered as a single 200 mg dose. If recrudescence is observed, a single 400 mg dose of OZ439 will be given. Treatment with OZ439 will be administered after an overnight fasting period of ≥ 6 hours. If dosing is to occur in the evening, subjects will be required to fast for ≥4 hours prior to receiving treatment. Participants will drink 200 mL of milk prior to drug administration, and then swallow the appropriate volume of OZ439 suspension. Subjects will be required to fast for a further six hours anytime after dosing with OZ439.
* Cohort 3 DSM265 will be administered as a single dose (400 mg) as described for cohort 1. No additional dose will be administered.
Interventions:
description: Oral suspension from bulk powder
name: DSM265
type: Drug
description: Oral suspension from powder in a bottle
name: OZ439
other_name: Artefenomel
type: Drug
Study arms:
design_group_description: Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment.
design_group_title: DSM265 P. falciparum
design_group_type: Experimental
design_group_description: Cohort 2: subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439. If recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439.
design_group_title: OZ439 P. vivax
design_group_type: Experimental
design_group_description: Cohort 3: subjects will be infected with P. vivax by IBSM, then treated with a single 400 mg dose of DSM265
design_group_title: DSM265 P. vivax
design_group_type: Experimental
Sponsor: MMV Medicines for Malaria Venture
Collaborators: Q-Pharm Pty Ltd.
QIMR Berghofer Medical Research Institute
Clinical Network Services Pty Ltd.
Drug name mappings:
name: Artefenomel Mesylate
lang: EN
name: DSM-265
lang: EN
Clinical trial NCT00667641: Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
Official title: Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway
Conditions: Breast Cancer
Colorectal Cancer
Head and Neck Cancer
Lung Cancer
Melanoma (Skin)
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Summary: RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel together with bortezomib may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of paclitaxel and bortezomib in treating patients with metastatic or unresectable malignant solid tumors.
Interventions:
description: Starting dose level 0.70mg/m2
name: bortezomib
type: Drug
description: Starting dose level 40mg/m2
name: paclitaxel
type: Drug
Study arms:
Sponsor: University of Medicine & Dentistry of New Jersey
Collaborators: National Cancer Institute
Drug name mappings:
name: 紫杉醇
lang: CN
name: Paclitaxel
lang: EN
name: パクリタキセル
lang: JP
name: 硼替佐米
lang: CN
name: Bortezomib
lang: EN
name: ボルテゾミブ
lang: JP
Clinical trial NCT00019019: Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
Official title: A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA
Conditions: Brain and Central Nervous System Tumors
Breast Cancer
Kidney Cancer
Lung Cancer
Lymphoma
Melanoma (Skin)
Ovarian Cancer
Small Intestine Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of carboxyamidotriazole and paclitaxel in treating patients with advanced solid tumors or refractory lymphomas.
Interventions:
name: carboxyamidotriazole
type: Drug
name: paclitaxel
type: Drug
Study arms:
Sponsor: National Institutes of Health Clinical Center
Collaborators: National Cancer Institute
Drug name mappings:
name: 紫杉醇
lang: CN
name: Paclitaxel
lang: EN
name: パクリタキセル
lang: JP
name: 羧胺三唑
lang: CN
name: Carboxyamidotriazole
lang: EN
Clinical trial NCT02603185: PhaseⅠFirst-in-Human Study of Hemay007 in Healthy Volunteers
Official title: A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Hemay007
Conditions: Inflammatory Bowel Disease
Summary: This phase I study designed in 3 parts is a randomized, placebo-controlled, sequential ascending-dose study of healthy volunteers. The safety, tolerability and pharmacokinetics of ascending single and multiple dose of Hemay007 will be assessed in Part 1 and Part 3, respectively. Food effect following a single oral dose will be evaluated in Part 2.
Interventions:
name: Hemay007
type: Drug
name: placebo
type: Drug
Study arms:
design_group_description: Part 1: Single ascending dose Group Hemay007 tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.<br/>Part 2: Food effect group Hemay007 tablets will be taken orally in single dose with a high-fat, high-calorie meal or at overnight fasting.<br/>Part 3: Multiple doses group Hemay007 tablets will be taken orally once daily in low, medium, high doses
design_group_title: Hemay007
design_group_type: Experimental
design_group_description: Part 1: Single ascending dose Group Placebo tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.<br/>Part 3: Multiple doses group Placebo tablets will be taken orally once daily in low, medium, high doses
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Hemay Pharmaceutical Pty Ltd
Collaborators: Tianjin Hemei Biological Technology Co.,Ltd.
Drug name mappings:
name: Hemay007
lang: EN
Clinical trial NCT04021563: The Safety, Tolerability, Pharmacokinetics(PK) of SR419 in Healthy Volunteers
Official title: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of SR419 in Healthy Volunteers
Conditions: Healthy Volunteers
Summary: This study is to evaluate the safety, tolerability, PK of SR419 in healthy volunteers.
Interventions:
description: Ascending single and multiple doses of SR419 orally
name: SR419
type: Drug
description: Ascending single and multiple doses of placebo orally
name: Placebo
type: Drug
Study arms:
design_group_description: Ascending single and multiple doses of SR419 orally
design_group_title: SR419
design_group_type: Experimental
design_group_description: Ascending single and multiple doses of placebo orally
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Shanghai SIMR Biotech Co., Ltd.
Collaborators: Syneos Health, Inc.
Drug name mappings:
name: SR-419
lang: EN
Clinical trial NCT06480201: Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Official title: Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Conditions: Healthy
Major Depressive Disorder
Treatment Resistant Depression
Summary: The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion. Our study design captures the clinical variation associated with real-world treatment resistant depression (TRD) patients and allows us to analyze the relative importance of GBP to antidepressant symptom reduction across the induction phase of treatment. If successful, it provides a compelling rationale for a larger prospective investigation of gamma dynamics as a moderator of outcome to varied TRD therapies which impact the balance of cortical excitation and inhibition.
Interventions:
description: Ketamine infusion amount is dictated by BMI, sex, and age.
name: Ketamine
type: Drug
description: Saline infusion amount is dictated by BMI, sex, and age.
name: Saline
type: Other
Study arms:
design_group_description: Healthy controls will receive one saline and ketamine infusion.
design_group_title: Healthy Controls
design_group_type: Active Comparator
design_group_description: Major Depressive Disorder participants will receive one saline and ketamine infusion.
design_group_title: Major Depressive Disorder
design_group_type: Active Comparator
design_group_description: Treatment Resistant Depression participants will receive 8 ketamine infusions where their first and fourth infusions are a saline and ketamine infusion.
design_group_title: Treatment Resistant Depression
design_group_type: Active Comparator
Sponsor: Texas A&M University
Collaborators: National Institute of Mental Health
Drug name mappings:
name: 盐酸氯胺酮
lang: CN
name: Ketamine Hydrochloride
lang: EN
name: ケタミン塩酸塩
lang: JP
Clinical trial NCT02234921: Pilot Study of DRibble Vaccine for Prostate Cancer Patients
Official title: A Pilot Study of DPV-001 DRibble Vaccine With Imiquimod in Advanced Prostate Cancer
Conditions: Adenocarcinoma of the Prostate
Summary: This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer.
Interventions:
description: A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
name: Cyclophosphamide
other_name: Cytoxan
type: Drug
description: DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.
name: DRibble Vaccine
other_name: DPV-001 DRibble vaccine
type: Biological
description: Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.
name: HPV Vaccinations
other_name: Ceravix
type: Biological
description: Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
name: Imiquimod
type: Drug
Study arms:
design_group_description: Patients will receive cyclophosphamide 3 days prior to the first of 9 planned DRibble vaccine injections. Imiquimod will be applied following 6 injections. Patients will receive 2 HPV vaccinations (Human papillomavirus).
design_group_title: DRibble Vaccine
design_group_type: Experimental
Sponsor: UbiVac, Inc.
Collaborators: Earle Chiles Research Institute
Providence Cancer Center
Providence Health & Services
Drug name mappings:
name: 环磷酰胺
lang: CN
name: Cyclophosphamide
lang: EN
name: シクロホスファミド水和物
lang: JP
name: 咪喹莫特
lang: CN
name: Imiquimod
lang: EN
name: イミキモド
lang: JP
name: Autophagosome vaccine (UbiVac)
lang: EN